Canine Arthritis Treatment Global Market Report 2024

The canine arthritis treatment market size has grown strongly in recent years. It will grow from $2.33 billion in 2023 to $2.35 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth observed in the historic period can be attributed to several factors, including the aging pet population, heightened awareness among pet owners regarding pet health, an emphasis on preventive care, rising disposable income among pet owners, and an increase in expenditure on veterinary care.

The canine arthritis treatment market size is expected to see strong growth in the next few years. It will grow to $2.9 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The projected growth in the forecast period can be attributed to several factors, including an increase in pet insurance coverage, a rise in cases of arthritis among pets, growing rates of pet ownership, an increasing demand for minimally invasive surgical procedures, and a higher prevalence of arthritis in dogs. Major trends expected in this period include the development of innovative treatments, advancements in veterinary medicine, a growing demand for advanced therapies, the integration of technology into veterinary care, and the adoption of innovative technologies to enhance pet healthcare.

The canine arthritis treatment market is set to grow, driven by the increasing rate of pet ownership. Pet ownership involves caring for domesticated animals for companionship and enjoyment, with factors such as lifestyle changes, pet humanization, and higher disposable incomes contributing to the rising trend. Pet owners utilize treatments for canine arthritis to manage symptoms and improve their dogs' quality of life and mobility. For example, in October 2023, the American Pet Products Association reported that 66% of US households, totaling 86.9 million, owned a pet, indicating the growth in pet ownership driving the canine arthritis treatment market.

Leading companies in this market are innovating treatments such as bedinvetmab injections to address canine joint health and mobility. Bedinvetmab, a monoclonal antibody injection targeting nerve growth factor (NGF) involved in pain, has gained FDA approval. For instance, Zoetis Inc. received FDA approval for Librela, the first monoclonal antibody for dogs, which inhibits canine NGF's biological activity related to pain regulation in osteoarthritis. Administered monthly via subcutaneous injection, Librela offers a convenient, long-term solution for managing canine osteoarthritis pain.

In August 2021, Elanco Animal Health Incorporated acquired Kindred Biosciences Inc. for $444 million, aiming to enhance its innovation, portfolio, and productivity strategy in canine arthritis treatment. This acquisition strengthens Elanco's research and development capabilities in biologics and monoclonal antibodies, aligning with its commitment to providing solutions for veterinarians and pet owners in the canine arthritis market.

Major companies operating in the canine arthritis treatment market are Merck & Co. Inc., Bayer AG, Eli Lilly and Company, Zoetis Inc., Boehringer Ingelheim Animal Health, Elanco Animal Health Incorporated, Royal Canin SAS, Virbac Group, Ceva Sante Animale S.A., Hill's Pet Nutrition Inc., Vetoquinol SA, Norbrook Laboratories Limited, American Regent Inc., Thorne Healthtech Inc., VetStem Inc., Eltech K-Laser s.r.l., Liquid Health Inc, Nutri-Vet LLC, OrthoPets LLC, Rejuvenate Bio Inc.

North America was the largest region in the canine arthritis treatment market in 2023. Asia-Pacifica is expected to be the fastest-growing region in the forecast period. The regions covered in the canine arthritis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the canine arthritis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Canine arthritis treatment involves various medical and therapeutic approaches aimed at addressing the chronic condition characterized by inflammation and progressive cartilage deterioration in a dog's joints. The goal is to reduce pain and inflammation, preserve joint function, and slow down disease progression.

The primary treatments for canine arthritis include drugs, supplements, surgical procedures, and other interventions. Canine arthritis drugs are medications specifically formulated to alleviate symptoms and manage arthritis in dogs. These drugs can be administered orally, parenterally (such as injections), or through other routes, targeting conditions such as osteoarthritis, rheumatoid arthritis, osteochondrosis, and traumatic arthritis. They are distributed through veterinary clinics, hospitals, retail pharmacies, and online platforms, catering to various end-users such as veterinary hospitals, drug stores, and e-commerce platforms.

The canine arthritis treatment research report is one of a series of new reports that provides canine arthritis treatment market statistics, including the canine arthritis treatment industry's global market size, regional shares, competitors with a canine arthritis treatment market share, detailed canine arthritis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the canine arthritis treatment industry. This canine arthritis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The canine arthritis treatment market includes revenues earned by entities by providing services such as extracorporeal shockwave therapy (ESWT), acupuncture, and hyaluronic acid supplements. The market value includes the value of related goods sold by the service provider or included within the service offering. The canine arthritis treatment market also includes sales of gabapentin, adequan canine, and metacam. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.